A5016975904- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Cancer Genomics and Diagnostics
- Acute Lymphoblastic Leukemia research
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
- Retinoids in leukemia and cellular processes
- Multiple Myeloma Research and Treatments
- MicroRNA in disease regulation
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Pancreatic and Hepatic Oncology Research
- Hematopoietic Stem Cell Transplantation
- Lung Cancer Treatments and Mutations
- Cancer-related gene regulation
- RNA modifications and cancer
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Kruppel-like factors research
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Hemoglobinopathies and Related Disorders
- Renal and related cancers
University Medical Center Freiburg
2016-2025
University of Freiburg
2016-2025
European Organisation for Research and Treatment of Cancer
2025
German Cancer Research Center
1995-2024
Universität Hamburg
2022
University Medical Center Hamburg-Eppendorf
2022
Deutschen Konsortium für Translationale Krebsforschung
2019-2021
Praxis für Hämatologie und Onkologie
2020
Justus-Liebig-Universität Gießen
2017
The Ohio State University
2009-2014
Purpose To analyze the frequency and associations with prognostic markers outcome of mutations in IDH genes encoding isocitrate dehydrogenases adult de novo cytogenetically normal acute myeloid leukemia (CN-AML). Patients Methods Diagnostic bone marrow or blood samples from 358 patients were analyzed for IDH1 IDH2 by DNA polymerase chain reaction amplification/sequencing. FLT3, NPM1, CEBPA, WT1, MLL mutational analyses gene- microRNA-expression profiling performed centrally. Results found...
A phase II clinical trial with single-agent decitabine was conducted in older patients (≥60 years) previously untreated acute myeloid leukemia (AML) who were not candidates for or refused intensive chemotherapy. Subjects received low-dose at 20 mg/m 2 i.v. over 1 h on days to 10. Fifty-three subjects enrolled a median age of 74 years (range, 60–85). Nineteen (36%) had antecedent hematologic disorder therapy-related AML; 16 complex karyotypes (≥3 abnormalities). The complete remission rate...
To evaluate the prognostic significance of international European LeukemiaNet (ELN) guidelines for reporting genetic alterations in acute myeloid leukemia (AML).We analyzed 1,550 adults with primary AML, treated on Cancer and Leukemia Group B first-line trials, who had pretreatment cytogenetics and, cytogenetically normal patients, mutational status NPM1, CEBPA, FLT3 available. We compared complete remission (CR) rates, disease-free survival (DFS), overall (OS) among patients classified into...
To analyze the prognostic significance of NPM1 mutations, and associated gene- microRNA-expression signatures in older patients with de novo, cytogenetically normal acute myeloid leukemia (CN-AML) treated intensive chemotherapy.One hundred forty-eight adults age >or= 60 years novo CN-AML, enrolled onto Cancer Leukemia Group B protocols 9720 10201, were studied at diagnosis for NPM1, FLT3, CEBPA, WT1 profiles.Patients mutations (56%) had higher complete remission (CR) rates (84% v 48%; P <...
Purpose To determine the frequency of TET2 mutations, their associations with clinical and molecular characteristics outcome, associated gene- microRNA-expression signatures in patients primary cytogenetically normal acute myeloid leukemia (CN-AML). Patients Methods Four-hundred twenty-seven CN-AML were analyzed for mutations by polymerase chain reaction direct sequencing established prognostic gene mutations. Gene- profiles derived using microarrays. Results found 23% patients, older age (P...
Purpose To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients primary cytogenetically normal acute myeloid leukemia (CN-AML) gene/microRNA expression signatures. Patients Methods Younger (< 60 years; n = 175) (≥ 225) CN-AML treated intensive cytarabine/anthracycline-based first-line therapy on Cancer Leukemia Group B protocols were centrally analyzed for by polymerase chain reaction direct sequencing established prognostic gene mutations....
Purpose To determine the frequency of DNMT3A mutations, their associations with clinical and molecular characteristics outcome, associated gene- microRNA-expression signatures in primary cytogenetically normal acute myeloid leukemia (CN-AML). Patients Methods Four hundred fifteen previously untreated adults were analyzed for mutations established prognostic gene expression markers. Gene- profiles derived using microarrays. Results Younger (< 60 years; n = 181) older (≥ 234) patients had...
Oncogenic JAK mutation sensitizes myeloproliferative neoplasms to immune checkpoint inhibition.
T cell–derived IFNγ and CD40L/IL-21R signals are crucial for the differentiation of human T-bet high CD21 low B cells.
Purpose To evaluate the prognostic significance of expression levels a single microRNA, miR-181a, in context established molecular markers cytogenetically normal acute myeloid leukemia (CN-AML), and to gain insight into leukemogenic role miR-181a. Patients Methods miR-181a was measured pretreatment marrow using Ohio State University Comprehensive Cancer Center version 3.0 arrays 187 younger (< 60 years) adults with CN-AML. Presence other prognosticators assessed centrally. A...
To evaluate the impact of miR-155 on outcome adults with cytogenetically normal (CN) acute myeloid leukemia (AML) in context other clinical and molecular prognosticators to gain insight into leukemogenic role this microRNA.We evaluated 363 patients primary CN-AML. levels were measured pretreatment marrow blood by NanoString nCounter assays that quantified expression encoding gene MIR155HG. All assessed centrally. miR-155-associated microRNA profiles derived using microarrays.Considering all...
Molecular risk stratification of acute myeloid leukemia (AML) is largely based on genetic markers. However, epigenetic changes, including DNA methylation, deregulate gene expression and may also have prognostic impact. We evaluated the clinical relevance integrating methylation information in AML.Next-generation sequencing analysis methylated identified differentially regions (DMRs) associated with mutations older (≥ 60 years) cytogenetically normal (CN) patients AML (n = 134). Genes...
Abstract Oncogenic Ras mutations occur in various leukemias. It was unclear if, besides the direct transforming effect via constant RAS/MEK/ERK signaling, an inflammation-related of KRAS contributes to disease. Here, we identify a functional link between oncogenic Kras G12D and NLRP3 inflammasome activation murine human cells. Mice expressing active hematopoietic system developed myeloproliferation cytopenia, which is reversed mice lacking system. Therapeutic IL-1-receptor blockade or...
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease. Circulating tumor cells (CTC) in the blood are hypothesized as means of systemic spread. Blood obtained from healthy donors and patients with PDAC was therefore subject to size-based CTC-isolation. We additionally compared Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations pancreatic CTC corresponding tumors, evaluated their significance prognostic markers. Samples 68 individuals (58 patients, 10 donors) were...
Circulating tumor DNA (ctDNA) has demonstrated great potential as a noninvasive biomarker to assess minimal residual disease (MRD) and profile genotypes in patients with non‐small‐cell lung cancer (NSCLC). However, little is known about its dynamics during after resection, or for predicting clinical outcomes. Here, we applied targeted‐capture high‐throughput sequencing approach ctDNA at various milestones assessed predictive value early‐stage locally advanced NSCLC. We prospectively enrolled...